Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04317664 · ClinicalTrials.gov registry record · Phase 3

Intervention to Improve Driving Practices Among High-Risk Teen Drivers

A Phase 3 study of Communication and Recidivism, sponsored by Ginger Yang.

Completed
Registry status
Phase 3
Development phase
240
Enrollment target
1
Study location

NCT04317664 is a Phase 3 study of Communication and Recidivism that has completed, run by Ginger Yang. The registered enrollment target is 240 participants, below the 1,414-participant average among 34 other Communication trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04317664, a Phase 3 study of Communication and Recidivism, has completed, sponsored by Ginger Yang.

COMPLETED
Registry status
Phase 3
Development phase
240 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to test the effects of an in-vehicle driving feedback technology, with and without parent communication training, on risky driving events, unsafe driving behaviors, and subsequent traffic violations among teens who have recently received a moving traffic violation.

Interventions

  • COMBINATION_PRODUCT In-vehicle device
  • BEHAVIORAL Parent Communication

Study Locations (1)

Ohio

  • Nationwide Children's Hospital - Columbus

Trial Details

FieldValue
Enrollment Target 240 participants
Start Date 2020-09-28
Est. Completion 2025-12-31
Phase Phase 3

Sponsor

Ginger Yang

3 total trials

What the Registry Record Tells You About NCT04317664

The ClinicalTrials.gov registry entry for NCT04317664 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,414-participant average among 34 other Communication trials with a reported enrollment target (83% lower). The listed sponsor is Ginger Yang, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Communication appearing as the primary indexed condition, and to 2 interventions - of which In-vehicle device is the first listed.

NCT04317664 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT04317664 about?

NCT04317664 is a clinical study titled "Intervention to Improve Driving Practices Among High-Risk Teen Drivers". The purpose of this study is to test the effects of an in-vehicle driving feedback technology, with and without parent communication training, on risky driving events, unsafe driving behaviors, and subsequent traffic violations among teens who have recently received a moving traffic violation.

What is the current status of trial NCT04317664?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 240 participants. The study started on 2020-09-28. Estimated completion is 2025-12-31.

What conditions does trial NCT04317664 study?

This clinical trial studies the following conditions: Communication, Recidivism, Drive, Feedback, Psychological.

What interventions are being tested in trial NCT04317664?

The interventions under investigation include: In-vehicle device (COMBINATION_PRODUCT), Parent Communication (BEHAVIORAL).

Who is sponsoring clinical trial NCT04317664?

This trial is sponsored by Ginger Yang, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04317664 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Communication

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.